Curaxin CBL0137 Eradicates Drug Resistant Cancer Stem Cells and Potentiates Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer

Oncotarget - United States
doi 10.18632/oncotarget.2701
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Antitumor Effect of the Curaxin CBL0137 on the Models of Colon Cancer

Advances in molecular oncology
2016English

Aspirin Inhibits Proliferation of Gemcitabine-Resistant Human Pancreatic Cancer Cells and Augments Gemcitabine-Induced Cytotoxicity

Acta Pharmacologica Sinica
MedicinePharmacology
2009English

Cancer Stem Cells in Pancreatic Cancer

Cancers
Cancer ResearchOncology
2010English

Establishment and Characterization of the Gemcitabine‑resistant Human Pancreatic Cancer Cell Line SW1990/gemcitabine

Oncology Letters
Cancer ResearchOncology
2019English

Fasting Cycles Potentiate the Efficacy of Gemcitabine Treatment in in Vitro and in Vivo Pancreatic Cancer Models

Oncotarget
Oncology
2015English

Novel Gemcitabine Conjugated Albumin Nanoparticles: A Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2017English

Targeting Pancreatic Cancer Stem Cells

Journal of Cancer Sciences
2015English

P8 Is a New Target of Gemcitabine in Pancreatic Cancer Cells

Clinical Cancer Research
Cancer ResearchOncology
2006English

GEMMs as Preclinical Models for Testing Pancreatic Cancer Therapies

DMM Disease Models and Mechanisms
ImmunologyMolecular BiologyBiochemistryMicrobiology NeuroscienceMedicineGenetics
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy